Table 2.
Genotypic and allelic frequencies for VDR gene polymorphisms and clinical parameters of patients with prostate cancer, benign prostatic hyperplasia and healthy volunteers
| SNP | PCa (N = 132) | BPH (N = 41) | Healthy volunteers (N = 169) | |||||
|---|---|---|---|---|---|---|---|---|
| N (%) | Age* | PSA* | N (%) | Age* | PSA* | N (%) | Age* | |
| FokI | ||||||||
| CC | 54.00 (40.91) | 65.08 (8.79) | 14.08 (18.35) | 18.00 (43.90) | 66.25 (10.67) | 18.30 (46.56) | 79.00 (46.75) | 23.00 (4.57) |
| CT | 62.00 (46.97) | 67.51 (8.41) | 19.21 (32.75) | 19.00 (46.34) | 70.00 (10.59) | 12.75 (16.73) | 76.00 (44.97) | 22.98 (4.31) |
| TT | 16.00 (12.12) | 65.53 (11.29) | 50.68 (123.35) | 4.00 (9.76) | 72.33 (5.77) | 8.27 (2.22) | 14.00 (8.38) | 22.86 (6.18) |
| Alleles C/T | 170/94 (64.39/35.61) | 55/27 (67.07/32.93) | 234/104 (69.23/30.77) | |||||
| §PHWE | 0.78 | 0.75 | 0.47 | |||||
| Pχ2 | PCa x BPH = 0.90 | PCa x Healthy = 0.42 | BPH x Healthy = 0.93 | |||||
| BsmI | ||||||||
| AA | 14.00 (10.61) | 64.31 (9.66) | 30.11 (57.48) | 5.00 (12.20) | 71.00 (8.21) | 3.53 (2.40) | 28.00 (16.57) | 23.37 (4.50) |
| AG | 63.00 (47.73) | 67.69 (8.24) | 17.09 (22.57) | 25.00 (60.98) | 66.80 (11.25) | 10.41 (14.68) | 70.00 (41.42) | 22.93 (4.78) |
| GG | 55.00 (41.67) | 65.31 (9.44) | 21.49 (61.54) | 11.00 (26.86) | 71.45 (8.71) | 26.14 (55.23) | 71.00 (42.01) | 22.91 (4.15) |
| Alleles A/G | 91/173 (34.47/65.53) | 35/47 (42.68/57.32) | 126/212 (37.28/62.72) | |||||
| §PHWE | 0.52 | 0.11 | 0.14 | |||||
| Pχ2 | PCa x BPH = 0.23 | PCa x Healthy = 0.28 | BPH x Healthy = 0.08 | |||||
| ApaI | ||||||||
| TT | 49.00 (37.12) | 65.74 (9.22) | 19.98 (36.07) | 18.00 (43.90) | 66.56 (10.78) | 9.72 (17.38) | 51.00 (30.18) | 22.36 (4.94) |
| TG | 59.00 (44.70) | 65.44 (9.29) | 25.48 (63.84) | 16.00 (39.02) | 69.57 (10.50) | 8.45 (6.10) | 89.00 (52.66) | 22.91 (4.33) |
| GG | 24.00 (18.18) | 69.30 (7.18) | 10.66 (12.26) | 7.00 (17.07) | 71.14 (9.23) | 37.11 (68.48) | 29.00 (17.16) | 24.77 (3.94) |
| Alleles T/G | 157/107 (59.47/40.53) | 52/30 (63.41/36.59) | 191/147 (56.51/43,49) | |||||
| §PHWE | 0.40 | 0.31 | 0.35 | |||||
| Pχ2 | PCa x BPH = 0.73 | PCa x Healthy = 0.35 | BPH x Healthy = 0.21 | |||||
| TaqI | ||||||||
| TT | 60.00 (45.45) | 66.09 (8.94) | 20.77 (60.47) | 13.00 (31.71) | 70.75 (8.66) | 23.79 (53.24) | 71.00 (42.01) | 23.33 (4.01) |
| TC | 62.00 (46.97) | 66.93 (8.92) | 17.59 (21.26) | 23.00 (56.10) | 66.38 (11.44) | 10.69 (15.05) | 75.00 (44.38) | 22.90 (5.00) |
| CC | 10.00 (7.58) | 63.25 (9.78) | 37.62 (72.71) | 5.00 (12.20) | 73.50 (6.24) | 6.03 (2.65) | 23.00 (13.61) | 22.40 (4.47) |
| Alleles T/C | 182/82 (68.94/31.06) | 49/33 (59.76/40.24) | 217/121 (64.20/35.80) | |||||
| §PHWE | 0.27 | 0.29 | 0.65 | |||||
| Pχ2 | PCa x BPH = 0.26 | PCa x Healthy = 0.25 | BPH x Healthy = 0.39 | |||||
Pχ2: P value of Chi square test
SNP single nucleotide polymorphism
* Mean (±SD)
§PHWE: Hardy–Weinberg equilibrium